Abstract
SARS-CoV-2 vaccine-acquired immunity provides robust cross-variant recognition, while infection-acquired immunity can be heterogenous, with disease severity often modulating post-recovery responses. We assessed antibody waning dynamics between infection- and vaccination-acquired immunity across variants of concern (VOC). mRNA vaccination induced potent, cross-VOC Spike recognition and functional responses, but waned more rapidly for Omicron Spike. Hospitalized individuals developed more durable functional responses with lower peaks compared to mRNA vaccination, while outpatients exhibited slower decay than inactivated vaccine recipients. Humoral decay for the receptor binding domain tracked with neutralizing antibody titers, while S2-directed responses tracked with antibody-dependent myeloid cellular phagocytosis. Boosting the recovered patients with mRNA or inactivated vaccines expanded humoral breadth, durability, and restored functional responses, eliminating the severity- and platform-associated decay differences. Therefore, post-recovery hybrid immunization compensates for this distinction and broadens humoral breadth, highlighting the value of boosting immunity in previously infected individuals.
One Sentence Summary Infection- and vaccine-acquired immunity to COVID-19 exhibit different functional antibody profiles, each characterized by distinct kinetics of waning over time.
Competing Interest Statement
The authors declare the following competing interests; Galit Alter is a founder/equity holder in Seroymx Systems and Leyden Labs. G.A. has served as a scientific advisor for Sanofi Vaccines. G.A. has collaborative agreements with GSK, Merck, Abbvie, Sanofi, Medicago, BioNtech, Moderna, BMS, Novavax, SK Biosciences, Gilead, and Sanaria. R.A.M. has served as a scientific advisor for Valneva SE. The remaining authors declare no competing interests.
Funding Statement
Massachusetts Consortium on Pathogen Readiness (MassCPR) (G.A. and R.P.M.) Gates Global Health Vaccine Accelerator Platform INV-001650 (G.A. and R.P.M.) NIH (2U19AI135995-06, U19AI42790-05, 1P01AI168347-01, P01AI165072-1, U01CA260476-0251) (G.A. and R.P.M.) FLUOMICS and SYBIL Consortium (NIH-NIAID grant U19AI135972) (RAM) Center for Research on Influenza Pathogenesis (CRIP), an NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C) (R.A.M.) FONDECYT 1212023 grant from ANID of Chile R.A.M.) FONDECYT 1221811 grant from ANID of Chile (N.D.T.) FONDECYT 11231122 grant from ANID of Chile (C.P.R.) Centro Ciencia & Vida, CCTE Basal FB210008 (N.D.T.) Postdoctoral grant FONDECYT 3190706 (C.P.R.) Postdoctoral grant FONDECYT 3190648 (J.L.) ANID Becas/Doctorado Nacional 21212258 (M.J.A.) Scholarship from Vicerrectoria de Investigacion de la Escuela de Graduados, Pontificia Universidad Catolica de Chile. (E.S.) The authors would like to thank the laboratory of Prof. Douglas Lauffenburger (Massachusetts Institute of Technology) for the critical evaluation of statistics in this manuscript. We also thank Mark and Lisa Schwartz, Terry and Susan Ragon, and the SAMANA Kay MGH Research Scholars award for their support. We also would like to thank Estefany Poblete for her technical assistance during sample processing.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee at Pontificia Universidad Catolica de Chile (PUC) gave ethical approval for this work; an informed written consent form was obtained under protocol 200829003.This work was also supervised and approved by the Emory University Institutional Review Board (IRB ID STUDY00005857) and the Mass General Institutional Review Board (IRB #2020P00955 and #2021P002628).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
